Matthew Wongchenko

Principal Scientific Researcher, Genentech

Matthew Wongchenko

Matthew Wongchenko has ten years of experience advancing oncology drug development projects, particularly through research on cell signaling and exploratory biomarker analysis. Since joining Genentech as Principal Scientific Researcher, Wongchenko has been instrumental in the clinical biomarker development of Zelboraf and Cotellic, and has contributed to regulatory filings to secure approval for their combined use in the treatment of BRAF-mutant metastatic melanoma.

Prior to joining Genentech in 2011, Wongchenko worked for both ARIAD Pharmaceuticals and OSI Pharmaceuticals. He has authored 14 publications in Nature, The Lancet and Clinical Cancer Research, among others.

Back to Top